ReviewNeurobiology of disease2019
Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
Review in Neurobiology of disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- An Exploratory, Randomized, Double-Blind Clinical Trial of Dipraglurant for Blepharospasm.Movement disorders : official journal of the Movement Disorder Society · 2024Trial
- α-Synuclein-Targeted Immunotherapies in Parkinson's Disease: In Silico, In Vitro and Clinical Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Role and mechanism of molecular hydrogen in the treatment of Parkinson's diseases.Frontiers in neuroscience · 2025Review
- Cardiovascular history and risk of idiopathic Parkinson's disease: a cross-sectional observational study.BMC neuroscience · 2024Observational
- Neurosurgical and pharmacological management of dystonia.World journal of psychiatry · 2024Review
- eIF2α phosphorylation evokes dystonia-like movements with D2-receptor and cholinergic origin and abnormal neuronal connectivity.bioRxiv : the preprint server for biology · 2024Article
- Paradoxical Gait Response to Levodopa in Parkin-Gene-Related Early-Onset Parkinson's Disease: Dopa Worsening Dystonia.Movement disorders clinical practice · 2024Article
- Genetic Update and Treatment for Dystonia.International journal of molecular sciences · 2024Review
- Striatal Hand Deformities in Parkinson's Disease: Hand Surgical Perspectives.Movement disorders clinical practice · 2022Article
- Cerebellar stimulation prevents Levodopa-induced dyskinesia in mice and normalizes activity in a motor network.Nature communications · 2022Article
- Impairment of sleep homeostasis in cervical dystonia patients.Scientific reports · 2022Article
- Co-Application of C16 and Ang-1 Improves the Effects of Levodopa in Parkinson Disease Treatment.Journal of inflammation research · 2022Article
- DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease.Movement disorders clinical practice · 2021Article
- Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia-Literature Review.Journal of clinical medicine · 2021Review
- The critical balance between dopamine D2 receptor and RGS for the sensitive detection of a transient decay in dopamine signal.PLoS computational biology · 2021Article
- Review
- Chronic Pain Treatment Strategies in Parkinson's Disease.Neurology international · 2020Review
- Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Review
- Medical and Surgical Treatments for Dystonia.Neurologic clinics · 2020Review
- Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson's Disease.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Dystonia and levodopa-induced dyskinesia (LID) are both hyperkinetic movement disorders. Dystonia arises most often spontaneously, although it may be seen after stroke, injury, or as a result of genetic causes. LID is associated with Parkinson's disease (PD), emerging as a consequence of chronic therapy with levodopa, and may be either dystonic or choreiform. LID and dystonia share important phenomenological properties and mechanisms. Both LID and dystonia are generated by an integrated circuit involving the cortex, basal ganglia, thalamus and cerebellum. They also share dysregulation of striatal cholinergic signaling and abnormalities of striatal synaptic plasticity. The long duration nature of both LID and dystonia suggests that there may be underlying epigenetic dysregulation as a proximate cause. While both may improve after interventions such as deep brain stimulation (DBS), neither currently has a satisfactory medical therapy, and many people are disabled by the symptoms of dystonia and LID. Further study of the fundamental mechanisms connecting these two disorders may lead to novel approaches to treatment or prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.